Published in Gene Therapy Weekly, October 12th, 2006
Study 1: According to a study from Italy, treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter (NIS) complementary deoxyribonucleic acid.
"One of the major limits of gene therapy with NIS, which enables cells to be subjected to radioiodine therapy, is that NIS-transfected cells rapidly release the intracellular iodine," wrote R. Elisei and colleagues, University of Pisa.
"We transfected human anaplastic (FRO) and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.